The Extraordinary General Meeting of Diamyd Medical AB (publ) held today decided
in accordance with the Board's resolution, to approve the agreement to sell all
shares in the subsidiary, Diamyd, Inc. to Periphagen Holdings, Inc.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical
development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s
development project within the area of diabetes consists of the protein GAD65
for the treatment and prevention of autoimmune diabetes. A Swedish researcher
-initiated Phase II study is ongoing to evaluate whether GAD65 can prevent type
1 diabetes in children who are at high risk of developing the disease. The
Company’s development projects for the treatment of chronic pain and neuropathy
uses the patented NTDDS (Nerve Targeting Drug Delivery System) platform to
administer therapeutic agents directly to the nervous system. The NTDDS platform
is being divested.
Diamyd Medical also has holdings in the companies Protein Sciences Corporation
(USA) and Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker:
DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC
Markets and the Bank of New York Mellon (PAL). Further information is available
on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420
